tb 500 ghk cu GHK-CU /BPC-157 / TB-500 ANTI-AGING BLEND BPC-157 + TB-500 + GHK-Cu

Though all individuals with favism show G6PD deficiency, not all individuals with G6PD deficiency show favism

Category 2 Bulk Substance Designation FDAs compounding pages list BPC-157 under Category 2 and describe concerns including immunogenicity risk (for some administration routes) and challenges with peptide-related impurities and characterization

AITC itself is a strong anti-oxidant molecule and through molecular docking studies of the current investigation, it is revealed that AITC does not counteract the anti-oxidant potential of GST and SULT thus sustaining their enzymatic activities

But unlike NSAIDs, which can impair healing when used too long, BPC-157 seems to modulate COX-2 without shutting down the protective aspects of inflammation

Both are studied to understand different aspects of the peptides efficacy and mechanism